DOI
https://doi.org/10.47689/2181-3663-vol4-iss2-pp43-52Keywords
schizophrenia , preventive medicine , epidemiology , pathogenesis , risk factors , immune hypothesis , psychiatryAbstract
This article examines schizophrenia as one of the priority scientific topics in preventive medicine. Analysis of literature from recent decades shows that, despite the century-long history of studying the disease, significant discrepancies in diagnostic approaches still persist, complicating the development of a unified concept. Modern studies confirm the role of hereditary predisposition, nervous system disorders, and exogenous factors (perinatal influences, psychoactive substances) in the development of the disease. Particular attention is paid to the study of positive, negative, and cognitive symptoms, their combinations, and their relationship with the bipolar spectrum of disorders.
The review details new hypotheses about the pathogenesis of schizophrenia, including immunological, neurodevelopmental, autoimmune, inflammatory, and cytokine hypotheses, emphasizing the interdisciplinary nature of the problem. Epidemiological data indicate a stable prevalence of the disease (0.3-0.7% of the world's population), gender and age differences, as well as high risks of disability and suicide. An increase in incidence is observed in countries with low levels of socio-economic development, which underscores the importance of early prevention and prospective monitoring.
The authors conclude that the accumulated clinical-epidemiological and fundamental research forms a scientifically based foundation for the implementation of preventive medicine in psychiatry. In this context, schizophrenia is considered a priority topic for developing new approaches to diagnosis, treatment, prognosis, and prevention, especially in regions with high risk and insufficient study of the problem.
References
Бархатова А.Н, Чуркина А.М., Штейнберг А.С. Полиморфный аффективный психоз: основания для диагностика БАР I типа. шизофрении или отдельной нозологической формы. Психиатрия. 2024:22(5): 68 – 74.
Гоголева ВС, Друцкая МС, Атретзаны КС – Н. Микроглия в гомеостазе центральной нервной системы и нейровоспалении. Молекулярная биология. 2019:53(5):790 – 798. doi: 10.1134/S0026898419050057.
Горюнов А.В. Эволюция взглядов на детскую шизофрению // Психиатрия. – 2024;22(5) – С. 107 – 116.
Горюнов АВ, Зверева НВ, Симонов АН, Каледа ВГ. Клинические особенности щизотипического расстройства в детском – подростковом им. С.С Корсакова. Спецвыпуски. 2022: 122(9 - 2): 6 – 11.
Горюнов АВ. Дискуссионные вопросы диагностики и теоретические модели шизофрении в детском возрасте. Журнал неврологии и психиатрии им. С.С Карсакова. 2024:124(7): 18 – 23.
Корнева ЕА. Пути взаимодействия нервной и иммунной систем: история современность, клиническое применение. Медицинская иммунология. 2020;22(3):405 – 418. doi: 10.15789/1563 – 0625 – PON – 1974.
Мазаева НА. Предвестники шизофрении: взгляд на проблему. Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2020. 3(22): 4 – 13.
Макушкин ЕВ. Синашкова НВ. Пережогин АО. Горюнов АВ. Шизофрения в детском и подростковом возрасте. Российский психиатрический Журнал. 2016:(6): 62 – 81. doi: 10.24411/1560 – 957 X – 2016 – 1 %. 25Х.
Петрова НН. Диагностика и терапия биполярного расстройства. Современная терапия психических расстройств 2024:2: 41 – 54. doi: 10.21265/ PSYPH. 2024.31.31.005.
Синякин ИА, Баталова ТА. Микроглия как ключевой компонент регуляции синаптической активности. Научное обозрение. Биологические науки. 2020;4:53 – 58. doi: 10.17513/srbs.1215.
Alkelai A, Greenbaum L, Shohat S, Povysil G, Malakar A, Ren Z, Motelow JE, Schechter T, Draiman B, Chitrit – Raveh E, Hughes D, Jobanputra V. Shifman S, Goldstein DB, Kohn Y. Genetic insights into childhood – onset schizophrenia: The field of clinical exome sequencing. Schizophr Res. 2023: 252: 138 – 145. doi. 10.1016/j.schres. 2022.12.033. Epub 2023 Jan 14. PMID: 36645932.
Arendt M, Rosenberg R, Foldager L, et al. Cannabis – induced psychosis and subsequent schizophrenia disorders: follow – up study of 535 incident cases. Br J Psychiatry 2005;187:510 – 5.
Barnes TR, Mutsatsa SH, Hutton SB, et al. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006;188:237 – 42.
Byrne M, Agerbo E, Ewald H, et al. Parental age and risk of schizophrenia: a case – control study. Archives of general psychiatry 2003;60(7):673 – 8.
Canetta S, Sourander A, Surcel HM, Hinkka – Yli – Salomaki S, Leiviska J, Kellendonk C, McKeague IW, Brown AS. Elevated maternal C – reactive protein and increased risk of schizophrenia in a national birth cohort. Am J Psychiatry. 2014;171(9):960 – 968. doi: 10.1176/appi.ajp.2014.13121579.
Cartisano T, Kicker J. Anti – N – methyl – D – aspartate receptor encephalitis in 7 – month old infact following influenza vaccination. Neurology. 2016;89(16 Supplement):5 – 136.
Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Not Rev Immunol. 2010;10(12):826 – 837. doi: 10.1038/nri2873 Epub 2010 Nov 19. PMID: 21088683; PMCID: PMC3114424.
Di Luzio M. Guerrera S, Pontillo M, Lala M, Casula L, Valeri G, Vicari S. Autism spectrum disorder, very – early onset schizophrenia and child disintegrative disorder: the challenge of diagnosis. A case – report study. Front Psychiatry. 2023: 14: 1212687. doi:10.3389/fpsyt.2029.1212687.
Eatan W, Mortensen PB, Agerbo E, et al. Coeliac disease and schizophrenia: population based case control study with linkage of Danish national registers. BMJ Clinical research ed 2004;328(7437):438 – 9.
Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothsis of schizophrenia. Physiol Behav. 2007;92(1 - 2):203 – 209. doi: 10.1016/j.physbeh.2007.05.025.
Frankle W. Schizophrenia: epidemiology, clinical features, course and outcome. // In Elsevier eBooks 2009; PP. 453 – 458). https://doi.org/10.1016/b978 - 008045046 - 9. 00527 – 1.
Frost JL, Schafer DP. Microglia: Architects of the Developing Nervous System. Trends Cell Biol. 2016;26(8):587 – 597. doi: 10.1016/j.tcb.2016.02.006.
Horvath S, Mirnics K. Immune system disturbances in schizophrenia. Biol Psychiatry. 2014;75(4):316 – 323. doi: 10.1016/j.biopsych. 2013.06.01.
Kendhari J, Shanker R. Young – walker L.A. Review of Childhood – Oset Schizophrenia. Focus (AM Psychiatr Publ). 2016:14(3): 328 – 332. doi. 10.1176/appi. focus. 20160007. Epub 2016 Jul 8. PMID: 31975813: PMCID: PMC 6526799.
Li N., Chen S., Wu Z., Dong J., et al. Secular trends in the prevalence of schizophrenia among different age, period and cohort groups between 1990 and 2019. // Asian Journal of Psychiatry – 2024, 101, 104192. https://doi.org/10.1016/j.ajp.2024.104192.
Liang K, Zhao L, Lei Y et al. Nonsuicidal self-injury behaviour in a city of China and its associationwith family environment, media use and psychopathology. ComprPsychiatry.2022;115:152311.https://doi.org/10.1016/j.comppsych.2022.152311.
Mckee AC, Daneshvar DH. The neuropathology of trau-matic brain injury. Handb Clin Neurol. 2015;127:45–66. doi: 10.1016/B978-0-444-52892-6.00004-0.
Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013;30(4):297 – 306. doi: 10.1002/da. 22084.
Miller B.J., Lemos H, Schooler N.R., Goff D.C. Kopelowicz A., Lauriello J. // Longitudinal study of inflammation and relapse in schizophrenia. Schizophrenia Research, - 2023. - 252; Б: 88 – 95. https://doi.org/10.1016/j.schres.2022.12.028.
Munn NA. Microglia dysfunction in schizophrenia: an integrative theory. Med Hypotheses. 2000 Feb;54(2):198 – 202. doi: 10.1054/mehy.1999.0018. PMID: 10790752.
Najas-Garcia A, Carmona VR, Gómez-Benito J. Trends in the Study of Motivation in Schizophrenia: ABibliometric Analysis of Six Decades of Research
(1956–2017). Front Psychol. 2018;9:63. doi: 10.3389/
fpsyg.2018.00063.
Omalu B. Chronic Traumatic Encephalopathy. Prog
Neurol Surg. 2014;28:38–49. doi: 10.1159/000358761.
Paudel A, Lamichhane A, Magar KR, Khanal GP. Non suicidal self injury and suicidal behavior among adolescents: co – occurrence and associated. riskfactors. BMC Psychiatry. 2022:22(1):96. https://doi.org/10.1186/s12888 - 022 - 03763 – z..
Pontillo M, Averna R. Tata MC. Chiappa F: Pucciarini ML, Vicari S. Neurodevelopmental Tracjectories and Clinical Profiles in a Sample of Children and Adolescents with Early – and Very – Early – Onset. Schizophrenia. Front Psychiatry. 2021:12:662093.doi.10.33891 fpsyt. 2021. 662093. PMID:34603093: PMCID: PMC 8481627.
Ran M., Wong Y.I. Marriage and outcomes of people with schizophrenia in China: 14 – year follow – up study. Schizophrenia Research. – 2016, 182 б. 49 – 54. https://doi.org/10.1016/j.schres.2016.10.034.
Ratajczak MZ, Pedziwiatr D, Cymer M, Kucia M, Kucharska – Mazur J, Samochowiec J. Sterile Inflammation of Brain, due to Activation of Innate Immunity, as a Culprit in Psychiatric Disorders. Front Psychiatry. 2018;9:60. doi: 10.3389/fpsyt.2018.00060 PMID: 29541038; PMCID: PMC5835766.
Reddy LF, Irwin MR, Breen EC, Reavis EA, Green MF. Social exclusion in schizophrenia: Psychological
and cognitive consequences. Journal of psychiatric research. 2019;114(3):120–125. doi: 10.1016/j.jpsychires.2019.04.010.
Regier D.A., Farmer M.E., Rae D.S. et al. One – month prevalence of mental disorders in the United States and sociodemographic characteristics: the Epidemiologic Catchment Area study // Acta Psychiatrica Scandinavica. 1993. Vol. 88. P. 35 – 47.
Saha S., Barendregt J.J., Vos T. Whiteford H., et al. Modelling disease frequency measures in schizophrenia epidemiology. // - 2008. Schizophrenia Research, 104(1 - 3), Б: 246 254. https://doi.org/10.1016/j.schres.2008.05.022.
Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Van Doren V, Genovese G, Rose SA, Handsaker RE; Schizophrenia Working Group of the Psychiatric Genomics Consortium: Daly MJ, Carroll MC, Stevens B, McCarroll SA. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177 – 183. doi: 10.1038/nature16549.
Shnayder NA, Khasanova AK, Strelnik AI, Al – Zamil M, Otmakhov AP, Neznanov NG, Shipulin GA, Petrova MM, Garganeeva NP, Nasyrova RF. Cytokine imbalance as a biomarker of treatment – resistant schizophrenia. Int J Mol Sci. 2022;23(19):11324. doi: 10.3390/ijms231911324.
Sontheimer H. Chapter 13 – Schizophrenia. In: Sonthimer H, editor. Diseases of the Nervous System. San Diego: Academic Press; 2015. p. 375 – 403.
Uher R, Pavlova B, Najafi S, Adepalli N, Ross B. Howes Wallis E, Freeman K, Parker P. Propper L. Palaniyappan L. Antecedent of major depressive bipolar abd psychotic disorders: A systematic review and meta – analysis of prospective studies. Newrosci Biobehav Rev. 2024: 160: 105625. doi. 10/1016/j. neubiorev. 2024. 105625. Epub 2024 Mar 15. PMID: 38494121.
Verdoux H., Cougnard A., Grolleau S., Besson R., et al. A survey of general practitioner`s knowledge of symptoms and epidemiology of schizophrenia. // European Psychiatry. - 2005;21(4), 238 – 244. https://doi.org/10.1016/j.eurpsy. 2005.05.013.
Wahbeh M.H., Avramopoulos D. Gene – Environment Interactions in Schizophrenia: a literature review. // Genes. – 2021. 12(12), с. 1850. https://doi.org/10.3390/genes12121850.
Zhao W., Zhang Q., Su Y., Chen X., et al. Effect of schizophrenia risk gene polymorphisms on cognitive and neural plasticity. // Schizophrenia Research. - 2022; 248, 173 – 179. https://doi.org/10.1016/j.schres.2022.08.014.
Downloads
53 21Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Неъматжон Мамасалиев, Шавкат Исламов

This work is licensed under a Creative Commons Attribution 4.0 International License.











